Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit (Diamond)

11. november 2026 opdateret af: Istituto Auxologico Italiano

Evidence-based Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit: an Observational Study

The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).

Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).

Undersøgelsestype

Observationel

Tilmelding (Anslået)

300

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

16 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Consecutive patients referred to the Syncope Unit for severe unexplained syncope

Beskrivelse

Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.

Exclusion Criteria: Non-severe syncope Definitions.

  • Unexplained syncope is defined as unexplained etiology or unexplained

  • Severe syncope is defined by the presence of one or more among the following:

    1. Suspected life-threatening arrhythmias

    2. Substantial impact on patient's quality of life (QoL)

      • Frequent episodes
      • Restriction of educational or occupational activities (including, but not limited to, unemployment)
      • Restriction of social or daily-life activities, e.g. when syncope occurs while driving
    3. High risk of clinically significant outcomes

      • Syncope associated with major injuries/trauma, i.e. head injury or fractures
      • Unpredictable syncope, i.e. without prodrome or identifiable triggers
    4. Presence of serious comorbidities, such as concomitant heart disease, neurologic disease, diabetes or renal failure

    5. Suspected Autonomic syncope overlapping with suspected psychogenic pseudosyncope

  • Non-severe syncope is defined by the presence of one or more among the following:

    1. Sporadic (isolated) episodes without major impact on patient's QoL
    2. Predictable syncope, i.e. syncope preceded by prodrome and/or occurring in association with identifiable triggers, with low risk of injuries

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Unexplained syncope

Syncope Unit

At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.
Tidsramme: through study completion, an average of 1 year
through study completion, an average of 1 year

Sekundære resultatmål

Resultatmål
Tidsramme
Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway
Tidsramme: through study completion, an average of 1 year
through study completion, an average of 1 year
Assessment of number and costs of resource utilization associated to the clinical practices
Tidsramme: through study completion, an average of 1 year
through study completion, an average of 1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

31. december 2026

Primær færdiggørelse (Anslået)

31. december 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

5. september 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

17. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 09X605

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .